Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases

Nat Rev Rheumatol. 2021 Oct;17(10):585-595. doi: 10.1038/s41584-021-00652-9. Epub 2021 Aug 2.

Abstract

Most rheumatic and musculoskeletal diseases (RMDs) can be placed along a spectrum of disorders, with autoinflammatory diseases (including monogenic systemic autoinflammatory diseases) and autoimmune diseases (such as systemic lupus erythematosus and antiphospholipid syndrome) representing the two ends of this spectrum. However, although most autoinflammatory diseases are characterized by the activation of innate immunity and inflammasomes and classical autoimmunity typically involves adaptive immune responses, there is some overlap in the features of autoimmunity and autoinflammation in RMDs. Indeed, some 'mixed-pattern' diseases such as spondyloarthritis and some forms of rheumatoid arthritis can also be delineated. A better understanding of the pathogenic pathways of autoinflammation and autoimmunity in RMDs, as well as the preferential cytokine patterns observed in these diseases, could help us to design targeted treatment strategies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Autoimmune Diseases* / genetics
  • Autoimmune Diseases* / immunology
  • Autoimmunity* / genetics
  • Autoimmunity* / immunology
  • Humans
  • Immunity, Innate / genetics
  • Immunity, Innate / immunology
  • Inflammation* / genetics
  • Inflammation* / immunology
  • Musculoskeletal Diseases* / genetics
  • Musculoskeletal Diseases* / immunology
  • Rheumatic Diseases / genetics
  • Rheumatic Diseases / immunology